Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Nouri

Medro
Graded #255

Higher grade

vs+8.800000000000004
Nouri
Graded #455

Lower grade

The verdict

Medro takes it — 63.6/100 to 54.8/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
50
45
Dose & formulationMedro +37
77
40
Clinical oversightMedro +7
71
64
Labs & monitoringNouri +1
52
53
FulfillmentMedro +5
92
87
Contract termsNouri +22
33
55
Medro · left barNouri · right bar

The numbers

MetricMedroNouri
WeighScore63.6/10054.8/100
GradeCC
Scorecard rank#255#455
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$299/mo (compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Nouri

Graded #455 · C

Strengths

  • Named clinical MSO partner (Wasef Health, PC; Michael Wasef, MD) with public contact email
  • Named 503A compounding pharmacy partner (Jungle Jim's Pharmacy, Fairfield OH) with full address
  • Available in all 50 states per the FAQ
  • Flat per-dose pricing within each tier — no dose-escalation surcharge
  • Nutrition and movement coaching included in the medication price

Where it loses points

  • Compounded medications only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Operating entity name not disclosed in the Terms of Service
  • Terms 'where we operate' language is slightly weaker than the FAQ's all-50-states claim
  • Video visit required in some states, but those states aren't listed
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard